

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	Continuation of <del>09/874,009</del>
				Filing Date	July 21, 2003 10/622,425
				First Named Inventor	Jeffrey WEITZ et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	GLYCO-12 C2

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office <sup>4</sup>	Number <sup>4</sup>	Kind Code <sup>4</sup> (if known)				
dk	B1	EP	0101141			04-22-1984		
	B2	WO	98/55515			12-10-1998		
	B3	EP	0244235			11-04-1987		
	B4	WO	92/18545			10-29-1992		
ch	B5	WO	01/02443			01-11-2001		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
dm	C1	XP-002151018; <i>Carbohydrate Research</i> , 80 (1980), pp. 131-145; "Periodate Oxidation and Alkaline Degradation of Heparin-related Glycans"		
	C2	D.A. Lane, et al., "Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4," <i>Biochem. J.</i> , (1984), vol. 218, pp. 725-732		
	C3	Jack Hirsh, M.D., McMaster University, Faculty of Health Sciences, Hamilton, Ontario, Canada, "Low Molecular Weight Heparins," (1994), Decker Periodicals, pp. 1-64		
	C4	Jack Hirsh, M.D., McMaster University, Faculty of Health Sciences, Hamilton, Ontario, Canada, "Low Molecular Weight Heparins - Second Ed.," (1996), Decker Periodicals, pp. 1-76		
dm	C5	Jack Hirsh, M.D., McMaster University, Faculty of Health Sciences, Hamilton, Ontario, Canada, "Low Molecular Weight Heparins - Third Ed.," (1999), Decker Periodicals, pp. 1-106		

Examiner Signature	<i>dkhane</i>	Date Considered	10/13/05
-----------------------	---------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.